Member Info for Timster

We will sell all we can make:
Healthcare services providers and governments are likely to be the largest volume customers of a professional use rapid antigen test and with an estimated price point in the mid-single digit GBP range. A higher price point is anticipated for sales to corporates for workforce testing.

DVLA lateral flow testing employees

What does this tell you?

The Group announced in Q4 2020 that it would focus on anterior nasal sampling because of the variability of saliva samples, although the test works with both sample types. The UK Department of Health and Social Care has also recently focused on nasal and other swab samples rather than saliva.

He's poirot now, but still quiet

I see Abingdon were up a bit today, sure that wasn't due to the pointless antibody test.

Seems we wait a year and all our news will come at once

--BAMS (mid to end March)
This evaluation is expected to continue for another two or three weeks and the Group is establishing outsourced manufacturing capacity for the BAMS tests in collaboration with Adeptrix so that it is in a position to formally validate the diagnostic product as soon as possible. Avacta is also in discussions with a large commercial partner to provide a route to market for the BAMS assay.

--- ISO accredited (end of March)
The Diagnostics Division has established a Quality Management System and the first external audit by the Group's Notified Body[2] (BSI Group) was passed in December successfully. The second and final audit is scheduled for March 2021. A positive outcome of the second audit will lead to ISO13485 accreditation. This certification sets the organisational and operational framework for all current and future diagnostic product developments and it is an essential accreditation that underpins future commercial success.

---LFT SALES (End of March)
As stated above, on the basis of these excellent initial data, the Group will now progress to a full clinical validation with a larger number of patient samples to CE mark the test for professional use, aiming to bring the test to market in Europe around the end of the first quarter of this year.

The Group continues its commercial discussions with potential customers for the AffiDX® SARS-CoV-2 Lateral Flow Rapid Antigen Test and expects demand to be present for rapid testing for at least two years and probably for longer. Only by having a high-quality test that identifies the majority of infectious individuals can this clinical need be translated into commercial success and the Group believes that the recent initial clinical data are extremely encouraging in that regard.

It was posted earlier but lost in the crap:
The Group announced in Q4 2020 that it would focus on anterior nasal sampling because of the variability of saliva samples, although the test works with both sample types. The UK Department of Health and Social Care has also recently focused on nasal and other swab samples rather than saliva.

In summary, the AffiDX® SARS-CoV-2 Lateral Flow Rapid Antigen Test has excellent analytical sensitivity (LOD) of 50 pg/ml S1 spike protein, which appears sensitive enough to detect the lowest viral loads of relevance to the Intended Use Case, with a read time of 20 minutes. As far the Group is aware, this is the most sensitive S1 spike lateral flow test available.

The analytical specificity of the Affimer reagents has been reported previously with no cross-reactivity with the S1 spike proteins from closely related coronaviruses: MERS-CoV S1, SARS-CoV-1 S1, HC0V-229E S1, HCoV-HKU1 S1, HCoV-NL63 S1 or HCoV-OC43 S1.

The test detects the D641G mutant of the original coronavirus and the Group expects that the test will also detect the newer coronavirus variants. Work is ongoing with Public Health England to confirm this.

Very clear why we changed to nasal swab. The government asked us to!

Dont have a quick scan keep scrolling, the full update makes for an incredible read
https://polaris.brighterir.com/public/avacta/news/rns/story/w98m11r

Heads or tails? I know I know it is accurate it's just deeks scare mongering

Innova or surescreen for sure

Let's not forget he's insane too :)

really good info DaddyPig, I missed the last time you posted it.

very interesting though.......

Probably, your guess is as good as anyone elses

Spot on Benbenbenben it doesn't take much detective work from that statement to determine why they changed sample type

Which will make it the test of choice for healthcare providers in the UK and the rest of the world

Best in the world

@doggy he replied to himself :)

See Seperate th read and Matt Damon point that appdx mobile app reader will be used so who cares

You know what sujood YOU are the messiah and were right all along